Результаты поиска

Inflammation in cancer: therapeutic opportunities from new insights.

As one part of the innate immune response to external stimuli, chronic inflammation increases the risk of various cancers, and tumor-promoting inflammation is considered one of the enabling characteristics of cancer development. Recently, there has been growing evidence on the role of anti-inflammation therapy in cancer prevention and treatment. And researchers have already achieved several noteworthy outcomes. In the review, we explored the underlying mechanisms by which inflammation affects the occurrence and development of cancer. The pro- or anti-tumor effects of these inflammatory factors

Совпадение в полном тексте источника
… et al., 2008 Pancreatic cancer | Inhibit | Overexpresses P21 and Bax | Balabanov D et al., 2019 Cervical cancer | Inhibit | Inhibits proliferation and promotes apoptosis by up-regulating the expression of TRAILR1 | Ha L et al., 2024 Skin cancer | Inhibit | Increases MHC class 1,P21 and Rb protein | Romee …

Резюме научных материалов, представленных ГКОМ 2019 : Берлин, Германия. 27 - 30 Март 2019

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

2020 CIS Annual Meeting: Immune Deficiency & Dysregulation North American Conference.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме книги: ISEV2017.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous lymphoid malignancy and the most common subtype of non-Hodgkin's lymphoma in adults, with one of the highest mortality rates in most developed areas of the world. More than half of DLBLC patients can be cured with standard R-CHOP regimens, however approximately 30 to 40 % of patients will develop relapsed/refractory disease that remains a major cause of morbidity and mortality due to the limited therapeutic options.Recent advances in gene expression profiling have led to the identification of at least three distinct molecular

The use of RNA-based treatments in the field of cancer immunotherapy.

Over the past several decades, mRNA vaccines have evolved from a theoretical concept to a clinical reality. These vaccines offer several advantages over traditional vaccine techniques, including their high potency, rapid development, low-cost manufacturing, and safe administration. However, until recently, concerns over the instability and inefficient distribution of mRNA in vivo have limited their utility. Fortunately, recent technological advancements have mostly resolved these concerns, resulting in the development of numerous mRNA vaccination platforms for infectious diseases and various t

The 11th NORDIC NUTRITION CONFERENCE NNC2016.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Proceedings of Reanimation 2023, the French Intensive Care Society International Congress.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

BACKGROUND: The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of risk factor exposure and attributable burden of disease. By providing estimates over a long time series, this study can monitor risk exposure trends critical to health surveillance and inform policy debates on the importance of addressing risks in context. METHODS: We used the comparative risk assessment framework developed for previous iterations of GBD to estimate levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years

P941 – P1197

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

BACKGROUND: How long one lives, how many years of life are spent in good and poor health, and how the population's state of health and leading causes of disability change over time all have implications for policy, planning, and provision of services. We comparatively assessed the patterns and trends of healthy life expectancy (HALE), which quantifies the number of years of life expected to be lived in good health, and the complementary measure of disability-adjusted life-years (DALYs), a composite measure of disease burden capturing both premature mortality and prevalence and severity of ill

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Е-постеры.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

BACKGROUND: Measurement of changes in health across locations is useful to compare and contrast changing epidemiological patterns against health system performance and identify specific needs for resource allocation in research, policy development, and programme decision making. Using the Global Burden of Diseases, Injuries, and Risk Factors Study 2016, we drew from two widely used summary measures to monitor such changes in population health: disability-adjusted life-years (DALYs) and healthy life expectancy (HALE). We used these measures to track trends and benchmark progress compared with e

Резюме: 32 Второй Конгресс ЭСП и Международный конгресс XXXIII МПД.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Larocca *Università Cattolica del Sacro Cuore, Rome, Italy Background & objectives: Despite the MSBT has been recently identified as a “synonymous” of non-invasive LGSC (niLGSC; WHO, 2014), on the base of the clinical-prognostic reports, few molecular studies are carried out on this pathological entity …

ИАНКОН 2023 Выдержки из плаката

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Proceedings of Réanimation 2020, the French Intensive Care Society International Congress.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

34th Европейский конгресс патологии - резюме.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

RESEARCH COMMUNICATIONS OF THE 34th ECVIM-CA CONGRESS.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.